Tear Interleukin Biomarkers After Glaucoma Treatment
NCT07592988
Eye Diseases, Glaucoma
Almaty, Kazakhstan
View Trial DetailsNCT Number: NCT01027312
To determine the clinical usefulness of a refined third-generation instrument - The Assessment of Ability Related to Vision (AARV) in establishing the amount of disability, charting the detrimental effects of progressive disease and establishing the beneficial effects of treatment
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
This research study is designed to test the usefulness and repeatability of testing how much disability is caused by vision loss due to glaucoma. We are recruiting 100 patients with glaucoma and 20 healthy (have no eye disease) individuals to be enrolled in this study. The healthy study participants will be enrolled in order to describe how a healthy individual will perform on the test designed to assess one's performance when completing ten activities of daily living.
Clinical testing will be conducted by binocular and monocular visual fields, contrast sensitivity and visual acuity. The NEI-VFQ 15 Quality of Life Questionnaire will be used to measure patients perception of how well they are doing.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Day 1, 1 week, 6 months, 1 year
Time frame: Day 1, 1 week, 6 months, 1 year
Wills Eye
Other
Reproducibility and Clinical Usefulness of AARV (Assessment of Ability Related to Vision)
Acronym: AARV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07592988
Eye Diseases, Glaucoma
Almaty, Kazakhstan
View Trial DetailsNCT07592923
Eye Diseases, Glaucoma
Almaty, Kazakhstan
View Trial DetailsNCT03076697
Age Related Macular Degeneration, Cardiovascular Diseases
View Trial DetailsNCT07763288
Blind Eye, Blindness
Nonthaburi, Thailand
View Trial Details